Breaking News, Collaborations & Alliances

Isis Earns $10M Biogen Milestone

Initiates IND-enabling studies for ISIS-BIIB3Rx

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $10 million milestone payment from Biogen Idec for the initiation of studies to support an IND for ISIS-BIIB3Rx, a development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.   ISIS-BIIB3Rx is the third drug Isis is developing with Biogen. Isis is eligible to receive as much as $215 million in additional milestone payments and license fees. Should Biogen exercise its option to exclusively license ISIS-BIIB3Rx, Isis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters